GLP-1 Peptide Exendin-4 Strengthens Bones in Diabetic Mice by Lowering a Key Fracture Protein | Research

The takeaway

Semaphorin 4D drives bone fragility in type 2 diabetes, and the GLP-1 peptide exendin-4 improves bone strength by reducing Sema4D levels — independent of blood sugar control.

Blood glucose is not the major factor
Sema4D, not blood sugar, drives bone fragility in diabetes. Exendin-4 improves bone by reducing Sema4D through the CRMP2 pathway, independent of glycemic control.

What the researchers found

Sema4D was identified as the key regulator of bone fragility in type 2 diabetes through proteomics and deep screening analysis. Exendin-4 (a GLP-1 receptor agonist) improved bone biomechanical properties by decreasing serum Sema4D levels and promoting osteogenesis via CRMP2 activation. Metformin had minimal direct effect on Sema4D but enhanced exendin-4's action through a miR-140-3p-STAT3-miR-3657 signaling cascade that increased GLP-1 receptor expression. Anti-Sema4D treatment alone improved bone strength comparably to the combination of metformin and exendin-4. Blood glucose control was not the primary factor in bone remodeling.

Why it matters

Fractures in diabetic patients are a major and growing clinical problem. Despite good blood sugar control, these patients continue to break bones because the underlying bone quality issue isn't about glucose — it's about Sema4D. This study provides both a diagnostic biomarker (blood Sema4D levels) and a therapeutic mechanism (GLP-1 peptide-mediated Sema4D reduction) that could guide fracture prevention in the hundreds of millions of people with type 2 diabetes.

How the study worked

Multi-technique study in T2DM mice using micro-CT for bone mass analysis, three-point bending for biomechanical strength, ELISA for protein expression, proteomics and deep screening for pathway discovery, immunoprecipitation-mass spectrometry for protein interactions, and dual-luciferase reporter assays for molecular signaling validation.

What this study cannot tell us

This is an animal study in diabetic mice, and results may not translate directly to human bone biology. The specific doses and treatment durations in mice may not correspond to clinical dosing. Anti-Sema4D treatment is not currently available as a clinical therapy. The study uses exendin-4 rather than clinically dominant GLP-1 drugs like semaglutide, and effects may differ between agents.

How to read the evidence

This is a preclinical mechanistic study in diabetic mice using advanced multi-omics techniques. While it provides compelling evidence for the Sema4D-bone fragility pathway, all findings require human validation.

When this study was published

Published in 2026, this is cutting-edge research using modern proteomics and deep screening techniques to identify Sema4D as a novel bone health biomarker in diabetes.

The bigger picture

This study adds bone protection to the growing list of GLP-1 peptide drug benefits beyond blood sugar control. The finding that exendin-4 improves bone strength through a specific molecular pathway (Sema4D/CRMP2) rather than through glucose lowering is significant because it suggests GLP-1 drugs may directly protect bone tissue. Combined with emerging evidence for cardiovascular, liver, and kidney protection, this further positions GLP-1 agonists as multi-organ protective agents in diabetes.

Questions still open

Do clinically used GLP-1 drugs like semaglutide reduce Sema4D levels in human patients?
Could blood Sema4D levels serve as a clinical biomarker for fracture risk in diabetic patients?
Would anti-Sema4D therapy be feasible and safe in humans for fracture prevention?

Common questions

Why do people with type 2 diabetes break bones more often?

Surprisingly, it's not because of weak bones in the traditional sense — diabetic patients often have normal or even high bone density on scans. The problem is bone quality: the internal architecture and strength are compromised. This study shows that a protein called Sema4D, elevated in diabetes, impairs bone remodeling and makes bones fragile despite appearing normal on imaging.

Could GLP-1 drugs like Ozempic help protect bones in diabetes?

This mouse study suggests yes — the GLP-1 peptide exendin-4 improved bone strength by reducing Sema4D levels. Clinical GLP-1 drugs have shown neutral or mildly positive effects on fracture rates in human studies. This research provides a molecular explanation for how they might protect bones and suggests that this benefit could be significant, though human trials specifically testing bone outcomes are needed.

Read the original research

Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.

Journal of advanced research, 79, 179-195

View on PubMed ↗Publisher’s paper ↗

Citation

Liu, Xuanchen; Wang, Mo; Xu, Bin; Ma, Xue; Jiang, Yangzi; Huang, Hai; Shi, Zengzeng; Wu, Hao; Wu, Zhigang; Guo, Shuo; Zhao, Jungang; Zhao, Jian; Li, Xiaokang; Liang, Li; Guo, Zheng; Shi, Lei; Sun, Chao; Wang, Ning. (2026). Discovery and identification of semaphorin 4D as a bioindicator of high fracture incidence in type 2 diabetic mice with glucose control.. Journal of advanced research, 79, 179-195. https://doi.org/10.1016/j.jare.2025.03.014